Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Hainsworth

Showing results (1-10 of 177) with videos related to

Pageof 18
Sort By:
Seminars in Oncology|February 14, 2002
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trialJohn D Hainsworth
The Oncologist|October 13, 2004
Practical aspects of weekly docetaxel administration schedulesJohn D Hainsworth
Arthritis Research & Therapy|June 8, 2004
Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritisJohn D Hainsworth
Seminars in Oncology|February 1, 2017
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trialJohn D Hainsworth
Seminars in Oncology|February 1, 2017
Prolonging remission with rituximab maintenance therapyJohn D Hainsworth
Seminars in Oncology|March 26, 2004
Prolonging remission with rituximab maintenance therapyJohn D Hainsworth
Seminars in Oncology|March 26, 2003
First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphomaJohn D Hainsworth
Chest Surgery Clinics of North America|December 11, 2002
Diagnosis, staging, and clinical characteristics of the patient with mediastinal germ cell carcinomaJohn D Hainsworth
Seminars in Oncology|January 31, 2009
Treatment for patients with unknown primary cancer and favorable prognostic factorsJohn D Hainsworth, Karim Fizazi
Drugs - Real World Outcomes|October 18, 2016
Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Rearrangement Presenting as Carcinoma of Unknown Primary Site: Recognition and Treatment ImplicationsJohn D Hainsworth, F Anthony Greco
Pageof 18

Showing results (1-10 of 177) with videos related to

Sort By:
Pageof 18
Seminars in Oncology|February 14, 2002
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trialJohn D Hainsworth
The Oncologist|October 13, 2004
Practical aspects of weekly docetaxel administration schedulesJohn D Hainsworth
Arthritis Research & Therapy|June 8, 2004
Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritisJohn D Hainsworth
Seminars in Oncology|February 1, 2017
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trialJohn D Hainsworth
Seminars in Oncology|February 1, 2017
Prolonging remission with rituximab maintenance therapyJohn D Hainsworth
Seminars in Oncology|March 26, 2004
Prolonging remission with rituximab maintenance therapyJohn D Hainsworth
Seminars in Oncology|March 26, 2003
First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphomaJohn D Hainsworth
Chest Surgery Clinics of North America|December 11, 2002
Diagnosis, staging, and clinical characteristics of the patient with mediastinal germ cell carcinomaJohn D Hainsworth
Seminars in Oncology|January 31, 2009
Treatment for patients with unknown primary cancer and favorable prognostic factorsJohn D Hainsworth, Karim Fizazi
Drugs - Real World Outcomes|October 18, 2016
Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Rearrangement Presenting as Carcinoma of Unknown Primary Site: Recognition and Treatment ImplicationsJohn D Hainsworth, F Anthony Greco
Pageof 18